Aspirin versus Aspirin and Fondaparinux Prior to Early Invasive Strategy in Patients with NSTEMI

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517229-18-00

Enrollment

5076

Registered

2025-01-22

Start date

2025-04-30

Completion date

Unknown

Last updated

2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-ST-Elevation Myocardial Infarction (NSTEMI)

Brief summary

Composite endpoint of: 30-day mortality, 30-day new MI and refractory ischemia resulting in acute CAG before scheduled

Detailed description

Composite of occurrence of death or new MI within 180 days, 1 year, 3 years, 5 years and 10 years., Incidence cerebrovascular accident (CVA) within 30 days including: Ischemic stroke and Transient ischemic attack (TIA), Length of hospital stay, Left ventricular ejection fraction (LVEF) at discharge

Interventions

DRUGACETYLSALICYLIC ACID

DRUGFONDAPARINUX SODIUM

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Composite endpoint of: 30-day mortality, 30-day new MI and refractory ischemia resulting in acute CAG before scheduled	—

Secondary

Measure	Time frame
Composite of occurrence of death or new MI within 180 days, 1 year, 3 years, 5 years and 10 years., Incidence cerebrovascular accident (CVA) within 30 days including: Ischemic stroke and Transient ischemic attack (TIA), Length of hospital stay, Left ventricular ejection fraction (LVEF) at discharge	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026